AGC Biologics and Calypso Biotech have entered into an agreement for the process development and cGMP manufacture of CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15 (IL-15). Under the agreement, AGC Biologics will develop and scale up a process for cGMP manufacture of CALY-002 in its facility in Copenhagen, Denmark to support Calypso’s clinical trials in Europe.   IL-15 is an immune checkpoint cytokine that controls inflammation as well as the fate of multiple immune ce...